Molecular pathways: Targeting proteasomal protein degradation in cancer

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 15-20

  Molineaux, Susan M ^a  

^a Calithera Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DELANZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MLN 9708; ONX 0912; ONX 0921; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; PYRAZINES; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84855430944     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0853     Document Type: Article

References (60)

1. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-90.
2. Bochtler M, Ditzel L, Groll M, Hartmann C, Huber R. The proteosome. Abstract Annu Rev Biophys Struct 1999;28:2985-317.
3. Driscoll JJ, Dechowdhury R. Therapeutically targeting the SUMOylation, Ubiquitination and proteasome pathways as a novel anticancer strategy. Target Oncol 2010;5:281-9.
4. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006;5:596-613.
5. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008;17:879-95. (Pubitemid 351864325)
6. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2003;2:623-9.
7. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-57. (Pubitemid 351469448)
8. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60. (Pubitemid 38579481)
9. Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-64. (Pubitemid 38812468)
10. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7. (Pubitemid 35334752)
11. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72. (Pubitemid 39371809)
12. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al.Aphase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17. (Pubitemid 36741588)
13. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
14. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-21. (Pubitemid 46152510)
15. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74. (Pubitemid 46655613)
16. Goy A, Younes A, McLaughlin P, Pro B,Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75. (Pubitemid 46224166)
17. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84. (Pubitemid 46237441)
18. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-72. (Pubitemid 44497496)
19. San Miguel JF, Schlag R, Khuageva N, Shpilberg O, Dimopoulos M, Kropff M, et al. MMY-3002: a phase 3 study comparing bortezomibmelphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2007;110:76.
20. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777-84. (Pubitemid 41739012)
21. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20. (Pubitemid 46638949)
22. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 2007;43:1125-33. (Pubitemid 46592015)
23. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8. (Pubitemid 28072702)
24. Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008;51:1068-72. (Pubitemid 351304717)
25. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010;70:1970-80.
26. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 2003;42:355-7. (Pubitemid 36176323)
27. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91. (Pubitemid 47037522)
28. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) 1992;45:1746-52. (Pubitemid 23015454)
29. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009;52:3028-38.
30. Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007;107:687-717. (Pubitemid 46502369)
31. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451-6. (Pubitemid 43363478)
32. Groll M, Potts BC. Proteasome structure, function, and lessons learned from beta-lactone inhibitors. Curr Top Med Chem 2011 Aug 9.
33. Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006;128:5136-41.
34. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 1996;271:7273-6.
35. Groll M, Kim KB, Kairies N, Huber R, Crews CM. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis of alpha',beta'-epoxyketone proteasome inhibitors. J Am Chem Soc 2000;122:1237-8. (Pubitemid 30117471)
36. Williamson MJ, Blank JL, Bruzzese FJ, Cao Y, Daniels JS, Dick LR, et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Mol Cancer Ther 2006;5:3052-61. (Pubitemid 46092046)
37. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem 2003;278:21517-25. (Pubitemid 36792549)
38. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19. (Pubitemid 41579835)
39. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008;111:2765-75.
40. Potts CB, Albitar XM, Anderson CK, Baritaki S, Berkers C, Bonavida B, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011;11:254-84.
41. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;5:1836-43. (Pubitemid 44323252)
42. Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol 2010;149:550-9.
43. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22. (Pubitemid 29269108)
44. Ardley HC, Hung CC, Robinson PA. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett 2005;579:571-6.
45. Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol 2004;14:703-11. (Pubitemid 39572556)
46. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90. (Pubitemid 350106321)
47. Stapnes C, Døskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136:814-28. (Pubitemid 46348414)
48. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010;116:4906-15.
49. Chen D, Frezza M, Schmitt S, Kanwar J, P Dou Q. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11:239-53.
50. Chari A, Mazumder A, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics 2010;4:273-87.
51. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901. (Pubitemid 47477266)
52. Richardson PG, Weller E, Lonial S, Jakubowiak J, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-86.
53. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010;51:1178-87.
54. Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2007;110:411.
55. Orlowski RZ, Stewart K, Vallone M, Molineaux C, Kunkel L, Gericitano J, et al. Safety and antitumor efficacy of the proteasome inhibitorcarfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results. Blood (ASH Annual Meeting Abstracts) 2007;110:409.
56. Siegel DSD, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2010;116:985.
57. Vij R, Kaufman JL, Jakubowiak AJ, Stewart AK, Jagannath S, Kukreti V, et al. carfilzomib: high single agent response rate with minimal neuropathy even in high-risk patients. Blood 2010;116:1938.
58. Jakubowiak AJ, Dytfeld D, Jagannath S, Vesole DH, Anderson TB, Nordgren BK, et al. Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I/II MMRC trial. Blood 2010;116:862.
59. AghajanianCA, Hamlin P,GordonDS, Hong M, Naing A,Younes A, et al. Phase I study of the novel proteasomeinhibitorNPI-0052 in patients with lymphoma and solid tumors. J Clin Oncol 26, 2008 (suppl; abstr 3574).
60. Papadopoulos KP, Mendelson DS, Tolcher AW, Patnaik A, Burris HA, Rasco DW, et al. A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. J Clin Oncol 29, 2011 (suppl; abstr 3075).